| P-selectin: Cell-adhesion molecule / selectin
P-selectin is a strong target because it is biologically actionable and already clinically validated in non-cancer disease. Crizanlizumab is a humanized anti–P-selectin antibody used to reduce vaso-occlusive crises in sickle cell disease, showing that P-selectin can be drugged therapeutically.
-In cancer, P-selectin is highly relevant to platelet-assisted metastasis.
| Field |
Suggested Entry |
| Target |
P-selectin / SELP / CD62P |
| Full Name |
Selectin P |
| Target Class |
Cell-adhesion molecule; selectin family |
| Main Ligands |
PSGL-1, sialyl-Lewis X/A-containing glycoproteins, tumor-associated mucins |
| Primary Biology |
Platelet adhesion, leukocyte rolling, endothelial activation, thrombosis, inflammation, platelet–tumor cell interaction |
| Cancer Relevance |
High: promotes platelet-assisted metastasis, tumor-cell adhesion, immune evasion, vascular arrest, thrombosis, and may serve as a tumor-vascular drug-delivery target |
| AD Relevance |
Low-medium: indirect relevance through platelet/endothelial activation, vascular inflammation, and BBB dysfunction; stronger evidence in stroke than AD |
| Therapeutic Direction |
Usually inhibit/block pathological P-selectin or P-selectin/PSGL-1 adhesion in metastasis, thrombosis, and vascular inflammation. May also be exploited for targeted drug delivery. |
|